Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes

Insulin-induced hypoglycemia is a major treatment barrier in type-1 diabetes (T1D). Accordingly, it is important that we understand the mechanisms regulating the circulating levels of glucagon. Varying glucose over the range of concentrations that occur physiologically between the fed and fuel-depri...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Kim, A, Knudsen, J, Madara, J, Benrick, A, Hill, T, Abdul Kadir, L, Kellard, J, Mellander, L, Miranda, C, Lin, H, James, T, Suba, K, Spigelman, A, Wu, Y, MacDonald, P, Wenstedt Asterholm, I, Magnussen, T, Christensen, M, Visboll, T, Salem, V, Knop, F, Rorsman, P, Lowell, B, Briant, L
Format:	Journal article
Język:	English
Wydane:	eLife Sciences Publications 2021

Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes

Podobne zapisy